Clinical Trial Update: Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 clinical trial evaluated the cognitive and neurophysiological effects of raloxifene in Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Raloxifene (raloxifene)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Alzheimer Disease | Phase 2, Phase 3 | Status: COMPLETED